ASXL2 and pancreatic adenocarcinoma: To investigate the prognostic significance of ASXL2 in PAAD patients, we divided the patients into high and low ASXL2 expression groups based on the optimal cutoff calculated via “survival” and “survminer” packages (Supplementary Figure 1A).